Multiplexed immunoassay panel identifies novel CSF biomarkers for alzheimer's disease diagnosis and prognosis

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Craig Schapiro, Rebecca ^a   Kuhn, Max ^b   Xiong, Chengjie ^a   Pickering, Eve H ^b   Liu, Jingxia ^a   Misko, Thomas P ^b   Perrin, Richard J ^a   Bales, Kelly R ^b   Soares, Holly ^b   Fagan, Anne M ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CALBINDIN; CYSTATIN C; EOTAXIN 3; FATTY ACID SYNTHASE; FIBRINOGEN; GROWTH REGULATED ALPHA PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PANCREAS POLYPEPTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN 2; TAU PROTEIN; TAU PROTEIN 181; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGE; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; COMPUTER PREDICTION; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOASSAY; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIPLEXED IMMUNOASSAY; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; ALGORITHM; ARTIFICIAL INTELLIGENCE; CEREBROSPINAL FLUID; DEMOGRAPHY; GENETICS; GENOTYPE; METHODOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ALGORITHMS; ALZHEIMER DISEASE; ARTIFICIAL INTELLIGENCE; BIOLOGICAL MARKERS; COGNITION DISORDERS; DEMOGRAPHY; FEMALE; GENOTYPE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE;

EID: 79955431733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018850     Document Type: Article

References (95)

1. Craig-Schapiro R, Fagan AM, Holtzman DM, (2009) Biomarkers of Alzheimer's disease. Neurobiol Dis 35: 128-140.
2. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K, (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4: 38-48.
3. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
4. Perrin RJ, Fagan AM, Holtzman DM, (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922.
5. Blennow K, Hampel H, (2003) CSF Markers for Incipient Alzheimer's Disease. Lancet Neurol 2: 605-613.
6. Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, Shah A, et al. (2006) Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans. Ann Neurol 59: 512-519.
7. Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D, (2007) Cerebrospinal fluid tau/Aβ42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349.
8. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1: 371-380.
9. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. (2009) Relationships between biomarkers in aging and dementia. Neurology 73: 1193-1199.
10. Andreasen N, Hess C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. (1999) Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: Differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch Neurol 56: 673-680.
11. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, et al. (2007) Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 12: 255-260.
12. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, et al. (2008) Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 29: 1466-1473.
13. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. (2009) Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 4: e6294.
14. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L, (2006) Association Between CSF Biomarkers and Incipient Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Follow-Up Study. Lancent Neurology 5: 228-234.
15. Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G, et al. (2007) CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 69: 631-639.
16. Sunderland T, Linker G, Mirza N, Putnam K, Friedman D, Kimmel L, et al. (2003) Decreased β-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289: 2094-2103.
17. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, et al. (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7: 125-133; discussion 173-180.
18. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. (2010) Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 119: 669-678.
19. Simonsen A, McGuire J, Hansson O, Zetterberg H, Podust V, Davies H, et al. (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64: 366-370.
20. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, Kapaki E, et al. (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24: 434-440.
21. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3: 1486-1494.
22. Davidsson P, Westman-Brinkmalm A, Nilsson C, Lindbjer M, Paulson L, Andreasen N, et al. (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. NeuroReport 13: 611-615.
23. Abdi F, Quinn J, Jankovic J, McIntosh M, Leverenz J, Peskind E, et al. (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9: 293-348.
24. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH, (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61: 120-129.
25. Puchades M, Folkesson Hansson S, Nilsson C, Andreasen N, Blennow K, Davidsson P, (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Mol Brain Res 118: 140-146.
26. Hu Y, Hosseini A, Kauwe J, Gross J, Cairns N, Goate A, et al. (2007) Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics- Clin Appl 1: 1373-1384.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E, (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
28. Morris JC, (1993) The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology 43: 2412-2414.
29. Storandt M, Grant E, Miller J, Morris J, (2006) Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 67: 467-473.
30. Petersen R, Smith G, Waring S, Ivnik R, Tabgalos E, Kokmen E, (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56: 303-308.
31. 11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67: 446-452.
32. Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
33. Team RDC (2010) R: A language and environment for statistical computing. R Foundation for Statistical Computing.
34. Xiong C, McKeel D, Miller J, Morris J, (2004) Combining correlated diagnostic tests---application to neuropathologic diagnosis of Alzheimer's disease. Medical Decision Making 24: 659-669.
35. Gerlach RW, Kowalski BR, Wold HOA, (1979) Partial least-squares path modelling with latent variables. Analytica Chimica Acta 112: 417-421.
36. Chun H, Keleş S, Sparse partial least squares regression for simultaneous dimension reduction and variable selection. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 72: 3-25.
37. Breiman L, (2001) Random Forests. Mach Learn 45: 5-32.
38. Friedman JH, (2001) Greedy Function Approximation: A Gradient Boosting Machine. The Annals of Statistics 29: 1189-1232.
39. Boser BE, Guyon IM, Vapnik VN, (1992) A training algorithm for optimal margin classifiers. Proceedings of the fifth annual workshop on Computational learning theory Pittsburgh, Pennsylvania, United States ACM.
40. Caputo B, Sim K, Furesjo F, Smola A, (2001) Appearance-based object recognition using SVMs: which kernel should I use? Proceedings of Neural Information Processing Systems Workshop on Statistical methods for Computational Experiments In Visual Processing and Computer Vision. Whistler.
41. Tibshirani R, Hastie T, Narasimhan B, Chu G, (2003) Class Prediction by Nearest Shrunken Centroids, with Applications to DNA Microarrays. Statistical Science 18: 104-117.
42. Hastie T, Tibshirani R, Friedman JH, (2001) The Elements of Statistical Learning. New York Springer-Verlag.
43. Hastie T, Tibshirani R, Buja A, (1993) Flexible Discriminant Analysis by Optimal Scoring. Journal of the American Statistical Association 89: 1255-1270.
44. Ban Y, Watanabe T, Suguro T, Matsuyama TA, Iso Y, Sakai T, et al. (2009) Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb 16: 179-187.
45. Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, et al. (2010) The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med 16: 116-121.
46. Popp J, Bacher M, Kolsch H, Noelker C, Deuster O, Dodel R, et al. (2009) Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 43: 749-753.
47. Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, et al. (2007) Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. BMC Neurol 7: 14.
48. Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ, (2007) Hemorheological mechanisms in Alzheimer's disease. Microcirculation 14: 627-634.
49. van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM, (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36: 2637-2641.
50. Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A, (2001) Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand 103: 166-174.
51. Martinez M, Fernandez-Vivancos E, Frank A, De la Fuente M, Hernanz A, (2000) Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res 869: 216-219.
52. Leyhe T, Hoffmann N, Stransky E, Laske C, (2009) Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int J Neuropsychopharmacol 12: 1319-1326.
53. Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, et al. (2005) Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 57: 373-380.
54. Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Fernandez-Viadero C, Pena N, et al. (2007) Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 116: 56-58.
55. Chiappelli M, Borroni B, Archetti S, Calabrese E, Corsi MM, Franceschi M, et al. (2006) VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuvenation Res 9: 485-493.
56. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 21: 9-15.
57. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al. (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23: 237-243.
58. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD, (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 12: 215-227.
59. Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, Janka Z, (2000) Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia. Acta Neurol Scand 101: 279-282.
60. Straface E, Matarrese P, Gambardella L, Vona R, Sgadari A, Silveri MC, et al. (2005) Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study. FEBS Lett 579: 2759-2766.
61. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, et al. (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70: 1664-1671.
62. Chuo LJ, Sheu WH, Pai MC, Kuo YM, (2007) Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Dement Geriatr Cogn Disord 23: 251-257.
63. Sundelof J, Arnlov J, Ingelsson E, Sundstrom J, Basu S, Zethelius B, et al. (2008) Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 71: 1072-1079.
64. Brettschneider J, Riepe MW, Petereit HF, Ludolph AC, Tumani H, (2004) Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus? J Neurol Neurosurg Psychiatry 75: 1614-1616.
65. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, et al. (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 16: 389-397.
66. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, et al. (2007) Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39: 1437-1439.
67. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A, (2007) Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils. Scand J Clin Lab Invest 67: 179-190.
68. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, et al. (2004) Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25: 1033-1043.
69. Tizon B, Ribe EM, Mi W, Troy CM, Levy E, (2010) Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis 19: 885-894.
70. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, et al. (2007) Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 39: 1440-1442.
71. Fabbro S, Seeds NW, (2009) Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. Journal of Neurochemistry 109: 303-315.
72. Melchor JP, Pawlak R, Strickland S, (2003) The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 23: 8867-8871.
73. Cacquevel M, Launay S, Castel H, Benchenane K, Cheenne S, Buee L, et al. (2007) Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol Dis 27: 164-173.
74. Oyama R, Yamamoto H, Titani K, (2000) Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim Biophys Acta 1479: 91-102.
75. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, et al. (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 66: 695-709.
76. Paul J, Strickland S, Melchor JP, (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204: 1999-2008.
77. Su JH, Anderson AJ, Cribbs DH, Tu C, Tong L, Kesslack P, et al. (2003) Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis 12: 182-193.
78. Erten-Lyons D, Jacobson A, Kramer P, Grupe A, Kaye J, (2010) The FAS gene, brain volume, and disease progression in Alzheimer's disease. Alzheimers Dement 6: 118-124.
79. Ethell DW, Kinloch R, Green DR, (2002) Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. Curr Biol 12: 1595-1600.
80. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, et al. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21: 7551-7560.
81. Burger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, et al. (2009) Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci 27: 517-523.
82. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP, (2009) VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci 283: 66-68.
83. Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, et al. (2010) Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J Neurochem 112: 66-76.
84. Cheng X, Yang L, He P, Li R, Shen Y, (2010) Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J Alzheimers Dis 19: 621-630.
85. Patel JR, Brewer GJ, (2008) Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. Exp Neurol 213: 93-100.
86. Zhao M, Cribbs DH, Anderson AJ, Cummings BJ, Su JH, Wasserman AJ, et al. (2003) The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain. Neurochem Res 28: 307-318.
87. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, et al. (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68: 903-912.
88. Guo Q, Christakos S, Robinson N, Mattson MP, (1998) Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc Natl Acad Sci U S A 95: 3227-3232.
89. Goodman JH, Wasterlain CG, Massarweh WF, Dean E, Sollas AL, Sloviter RS, (1993) Calbindin-D28k immunoreactivity and selective vulnerability to ischemia in the dentate gyrus of the developing rat. Brain Res 606: 309-314.
90. Mattson MP, Rychlik B, Chu C, Christakos S, (1991) Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28k in cultured hippocampal neurons. Neuron 6: 41-51.
91. Prehn JH, Bindokas VP, Jordan J, Galindo MF, Ghadge GD, Roos RP, et al. (1996) Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol 49: 319-328.
92. Iacopino AM, Christakos S, (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A 87: 4078-4082.
93. Lechner T, Adlassnig C, Humpel C, Kaufmann WA, Maier H, Reinstadler-Kramer K, et al. (2004) Chromogranin peptides in Alzheimer's disease. Exp Gerontol 39: 101-113.
94. Iritani S, Niizato K, Emson PC, (2001) Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease. Neuropathology 21: 162-167.
95. Greene JR, Radenahmad N, Wilcock GK, Neal JW, Pearson RC, (2001) Accumulation of calbindin in cortical pyramidal cells with ageing; a putative protective mechanism which fails in Alzheimer's disease. Neuropathol Appl Neurobiol 27: 339-342.